Follistatin

Follistatin · FST · FS · Aktivin-bindendes Protein · FS-288 / FS-315 (Isoformen) · FS344 (Spleißvariante/Transkript; kodiert die zirkulierende FS-315-Isoform; in Gentherapie-Studien verwendet)

Investigational

Follistatin is an endogenous glycoprotein that binds and neutralizes various signaling molecules of the TGF-β family — above all activin and myostatin (GDF-8). Because myostatin curbs muscle growth, inhibiting myostatin is regarded as a possible approach to preserving or building muscle mass. The bulk of the robust data comes from animal models and gene-therapy approaches, in which the follistatin gene was delivered into muscle via a viral vector; the transcript used was often FS344, which after cleavage of the signal peptide encodes the mature, freely circulating FS-315 isoform. Early, very small clinical trials in muscle diseases exist. Important for context: there is no robust evidence for freely obtained “follistatin peptide” to enhance performance in healthy people, and follistatin is not approved as a medicine anywhere. Much of what is claimed about follistatin on the gray market relies on gene-therapy or animal data and cannot be transferred to unverified preparations.

Regulatory status

In clinical trials only · not approved

Investigational compound from muscle and gene-therapy research — not approved as a medicine in any region.

Drug class

Endogenous glycoprotein (activin-binding protein); antagonist of the TGF-β/myostatin signaling pathways. Pure research/investigational compound, not an approved medicine.

Half-life (informative)

For native, circulating follistatin, the literature describes very short residence times in the blood (range of minutes); robust, standardized half-life figures for therapeutic use in humans are lacking. In the gene-therapy approaches, what matters is not a substance half-life but the duration of gene expression in the muscle.

Studied in the literature

In research it has been studied predominantly as a gene-therapy approach: the follistatin gene — often the FS344 transcript, which encodes the mature FS-315 isoform — was introduced directly into the muscle (intramuscularly) via an adeno-associated virus (AAV) — first in animal models, later in very small clinical trials. This is a description of the study design, not a usage recommendation.

Mechanism of action

Follistatin binds ligands of the TGF-β superfamily with high affinity, in particular activin and myostatin (GDF-8), and sequesters them outside the cell. As a result, these signaling molecules can no longer dock onto their cell-surface receptors (type II activin receptors, ActRIIA/ActRIIB). Because myostatin normally limits muscle growth, its inhibition leads in animal models to enlarged muscle fibers (hypertrophy). Through activin binding, follistatin simultaneously affects its originally described function — the inhibition of FSH release from the pituitary gland. This dual role (muscle and hormone system) is one reason why the systemic effects in humans are considered not yet sufficiently understood.

A central research problem was to avoid systemic effects via the activin axis (including on the hormone system). The transcript chosen was FS344, which encodes the mature FS-315 isoform — the freely circulating form that is more weakly bound to tissue and the cell surface (in contrast to the shorter, more strongly matrix-bound FS-288 isoform) — together with local, muscle-targeted delivery, in order to limit such off-target effects. Data on freely available “follistatin peptide” as an injectable or other preparation cannot be equated with these gene-therapy data.

Research history

Follistatin was isolated in 1987 by a research group at the Salk Institute (Ueno, Ling, Ying, Esch, Shimasaki, Guillemin) from porcine follicular fluid and named after its originally observed effect: the inhibition of FSH release. Only later did its role as a binding protein for activin and myostatin come to the fore. With the discovery that myostatin limits muscle growth (myostatin-deficient animals and humans show markedly more muscle mass), follistatin became interesting for muscle research as a natural myostatin antagonist. In 2009, gene-therapy experiments in macaques (AAV1-FS344) showed sustained increases in muscle size and strength; building on this, a phase 1/2a gene-therapy trial was conducted in Becker muscular dystrophy and sporadic inclusion body myositis (NCT01519349, Nationwide Children's Hospital).

Regulatory status by region

USA·Not approved by the FDA

Follistatin gene therapy was studied in a registered, now-completed phase 1/2a trial (NCT01519349) in muscle diseases; there is no marketing authorization status.

EU·Not approved as a medicine

No EMA approval as a medicine; at most a subject of research. Freely traded preparations are not tested as medicines.

Worldwide·Experimental / research status

Data come predominantly from animal models and very small clinical trials; no established approval for broad use.

Research areas

Muscle wasting in muscular dystrophies (e.g. Becker muscular dystrophy) as a gene-therapy approach
Sporadic inclusion body myositis (sIBM)
Age-related muscle loss (sarcopenia) and muscle-weakening diseases — as a research hypothesis, not a proven therapy
Basic research on the myostatin/activin signaling axis and muscle hypertrophy
Role of follistatin in the hormone system (activin/FSH regulation)

Documented effects (from the literature)

In animal models and gene-therapy approaches: increase in muscle size and strength, fiber hypertrophy (especially fast type-2 fibers)
In the phase 1/2a gene-therapy trial in Becker muscular dystrophy: in some of those treated, improvements in the 6-minute walk test as well as tissue changes (less fibrosis, more normal fiber distribution), in others no response
In the reported studies, no serious adverse events were described; liver, kidney and blood values remained unremarkable within the range examined

Safety concerns & caution

The human evidence is very thin: only very small numbers of cases, short observation periods and inconsistent responses — no general efficacy or safety conclusions can be drawn from this
Follistatin simultaneously affects the activin/FSH axis; possible long-term consequences of broader systemic inhibition (including on the hormone balance) have not been sufficiently studied in humans
Theoretical concerns with persistently increased muscle growth (e.g. strain on tendons/joints, heart muscle) have not been conclusively clarified
Gene therapy is a fundamentally different approach from an injectable peptide — favorable data from AAV studies say nothing about the safety of freely traded preparations

Risks of gray-market purchase

Gray-market preparations sold as “follistatin” or “follistatin-344” are not tested; their identity, purity, content and sterility are unknown
Marketing often improperly transfers spectacular gene-therapy or animal data to unverified products and creates a false impression of efficacy and safety
No medical monitoring, no quality control and no legal safeguards; contaminants or mislabeling are possible
Legal status: not an approved medicine — acquisition and use outside of trials operate in a gray area with unclear liability and health risks

Frequently asked questions

Does follistatin simply build muscle because it inhibits myostatin?

In animal models, strong inhibition of myostatin does indeed lead to more muscle mass, and follistatin is an effective natural antagonist. In humans, however, the most robust data come from gene-therapy approaches in very small trials in muscle diseases, with inconsistent responses. Simple muscle building in healthy people through an obtained preparation is therefore not proven.

Is the freely available “follistatin peptide” the same as in the studies?

No. The positive study results are based predominantly on the follistatin gene being delivered locally into the muscle via a viral vector — a completely different approach from an injectable peptide from the gray market. The study data cannot be transferred to such unverified products.

Is follistatin approved as a medicine?

No. Follistatin is not approved as a medicine in any region. It is an investigational and research compound; clinical experience is limited to individual, small studies.

Sources

Primary and reference sources for your own reading.

Related substances

KisspeptinInvestigational

Unfamiliar terms? Look them up in the glossary or read the fundamentals.

This profile is for information and education only. It is not medical advice and deliberately contains no dosing or usage details. Decisions about use belong in a doctor’s hands.

Last reviewed: June 2026